FY2026 EPS Estimate for TG Therapeutics Decreased by Analyst

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at Cantor Fitzgerald lowered their FY2026 earnings estimates for shares of TG Therapeutics in a report issued on Tuesday, November 4th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the biopharmaceutical company will post earnings per share of $1.63 for the year, down from their previous forecast of $1.79. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share.

Several other brokerages also recently weighed in on TGTX. B. Riley raised TG Therapeutics to a “strong-buy” rating in a research note on Tuesday. The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 price objective on the stock in a research note on Thursday, July 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a research report on Wednesday, October 8th. HC Wainwright started coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $50.25.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $34.04 on Wednesday. TG Therapeutics has a 12-month low of $25.28 and a 12-month high of $46.48. The company has a market cap of $5.40 billion, a PE ratio of 92.00 and a beta of 1.97. The stock has a 50 day simple moving average of $33.77 and a 200-day simple moving average of $34.74. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping the consensus estimate of $0.24 by $2.19. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The firm had revenue of $161.71 million during the quarter, compared to analysts’ expectations of $152.12 million. During the same quarter in the prior year, the firm earned $0.02 EPS. TG Therapeutics’s quarterly revenue was up 92.7% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS.

Institutional Trading of TG Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. Smartleaf Asset Management LLC grew its position in TG Therapeutics by 21.0% in the third quarter. Smartleaf Asset Management LLC now owns 2,693 shares of the biopharmaceutical company’s stock worth $99,000 after buying an additional 467 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 486 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of TG Therapeutics by 4.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 53,963 shares of the biopharmaceutical company’s stock worth $1,949,000 after acquiring an additional 2,281 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of TG Therapeutics by 573.3% during the third quarter. Jones Financial Companies Lllp now owns 9,931 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 8,456 shares during the period. Finally, AlphaQuest LLC lifted its holdings in shares of TG Therapeutics by 3,065.2% during the third quarter. AlphaQuest LLC now owns 4,273 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 4,138 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director owned 94,061 shares of the company’s stock, valued at $3,032,526.64. The trade was a 18.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 10.64% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.